Chronic Myeloid Leukemia
作者： Charles L. Sawyers
DOI: 10.1056/NEJM199904293401706
关键词: Tyrosine kinase 、 Chronic phase chronic myelogenous leukemia 、 Myeloid leukemia 、 Chromosomal translocation 、 Chronic myelogenous leukemia 、 Immunopathology 、 Immunology 、 Medicine 、 Leukemia 、 Signal transduction 、 General Medicine
摘要: Over the past twenty years, clinical and laboratory studies have led to important new insights into biology of chronic myeloid leukemia. Basic science has defined molecular pathogenesis leukemia (CML) as unregulated signal transduction by Bcr-Abl tyrosine kinase. Clinical demonstrated that CML can be curable through immune-mediated elimination cells allogeneic T lymphocytes. Recently, specific inhibition kinase been found active in managing disease.
springer.com
lls.org 参考文章(117)
Mie Nieda, Andrew Nicol, Akiko Kikuchi, Koichi Kashiwase, Kerry Taylor, Kenji Suzuki, Kenji Tadokoro, Takeo Juji, Dendritic Cells Stimulate the Expansion of bcr-abl Specific CD8+ T Cells With Cytotoxic Activity Against Leukemic Cells From Patients With Chronic Myeloid Leukemia Blood. ,vol. 91, pp. 977- 983 ,(1998) , 10.1182/BLOOD.V91.3.977
AB Deisseroth, Z Zu, D Claxton, EG Hanania, S Fu, D Ellerson, L Goldberg, M Thomas, K Janicek, WF Anderson, Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. ,vol. 83, pp. 3068- 3076 ,(1994) , 10.1182/BLOOD.V83.10.3068.3068
T Skorski, P Kanakaraj, M Nieborowska-Skorska, MZ Ratajczak, SC Wen, G Zon, AM Gewirtz, B Perussia, B Calabretta, Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells Blood. ,vol. 86, pp. 726- 736 ,(1995) , 10.1182/BLOOD.V86.2.726.BLOODJOURNAL862726
U. Matulonis, J. D. Griffin, Ravi Salgia, K. Okuda, Y. Kanakura, B. Druker, Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Experimental Hematology. ,vol. 22, pp. 1111- 1117 ,(1994)
HJ Kolb, J Mittermuller, C Clemm, E Holler, G Ledderose, G Brehm, M Heim, W Wilmanns, Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients Blood. ,vol. 76, pp. 2462- 2465 ,(1990) , 10.1182/BLOOD.V76.12.2462.2462
TP Hughes, GJ Morgan, P Martiat, JM Goldman, Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood. ,vol. 77, pp. 874- 878 ,(1991) , 10.1182/BLOOD.V77.4.874.874
M M Horowitz, P A Rowlings, J R Passweg, Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplantation. ,(1996)
RA Mandanas, DS Leibowitz, K Gharehbaghi, T Tauchi, GS Burgess, K Miyazawa, HN Jayaram, HS Boswell, Role of p21 RAS in p210 bcr-abl Transformation of Murine Myeloid Cells Blood. ,vol. 82, pp. 1838- 1847 ,(1993) , 10.1182/BLOOD.V82.6.1838.BLOODJOURNAL8261838
Shikha Bose, Michael Deininger, Joanna Gora-Tybor, John M Goldman, Junia V Melo, None, The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease Blood. ,vol. 92, pp. 3362- 3367 ,(1998) , 10.1182/BLOOD.V92.9.3362
MJ Barnett, CJ Eaves, GL Phillips, RD Gascoyne, DE Hogge, DE Horsman, RK Humphries, HG Klingemann, PM Lansdorp, SH Nantel, Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study [see comments] Blood. ,vol. 84, pp. 724- 732 ,(1994) , 10.1182/BLOOD.V84.3.724.BLOODJOURNAL843724